Intravenous Fosfomycin Treatment for Carbapenem-Resistant Klebsiella pneumoniae in the United States

Abstract

Get full access to this article

View all access options for this article.

References

Kyle

Stollings

White

Noto

Wheeler

. Fosfomycin for multidrug treatment of Klebsiella pneumoniae carbapenemase bacteremia. Ann Pharmacother. 2015;49:366-367.

Varghese

Roberts

Lipman

. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27:19-34.

Navarro-San Francisco

Mora-Rillo

Romero-Gómez

. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19:E72-E79.

Pontikis

Karaiskos

Bastani

. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52-59.

Michalopoulos

Virtzili

Rafailidis

Chalevelakis

Damala

Falagas

. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16:184-186.

Karageorgopoulos

Miriagou

Tzouvelekis

Spyridopoulou

Daikos

. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother. 2012;67:2777-2779.